Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erbium laser plus thalidomide for recurrent oral ulcers
ChiCTR2500098391Phase 4Not yet recruiting
- Sponsor
- Suining Central Hospital
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of thalidomide in aphthosis (RAS) (2 arms), sponsored by Suining Central Hospital. Primary endpoints: Overall treatment effect, Ulcer healing time and 3 more. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
thalidomide
03
Conditions
aphthosis (RAS)
Beyond the preview
Go deeper on ChiCTR2500098391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098391.